Site Search

Results

Search Results : 1087

1 2 … 94 95 96 … 108 109

Clear All Filters

Abemaciclib in combination with fulvestrant for advanced or metastatic breast cancer after prior endocrine therapy

Breast cancer, a cancer that develops from the tissues of the breast, is the most common cancer in the UK. There are many types of breast cancer and they are often grouped based on the presence or absence of some specific types of proteins (‘receptors’) in the cells of the patient. The most common type […]

Setmelanotide for pro-opiomelanocortin deficiency obesity

Body fat and food intake are regulated by signals from the brain to the gut. One of the important hormones that is responsible for this is pro-opiomelanocortin (POMC). In a very small group of people there is a lack of this hormone (due to a genetic mutation), referred to as POMC deficiency. This causes severe […]

Trastuzumab Emtansine for HER2-positive breast cancer - adjuvant

Breast cancer is the most common cancer in the UK. One type of breast cancer is called HER2-positive. HER is a protein that is found in large amounts on the surface on some cancer cells where it stimulates their growth. HER2-positive breast cancer tends to grow faster than HER2-negative breast cancer. Treatment of early stage […]

Ribociclib (Kisqali) and fulvestrant for advanced HR positive, HER2‐negative breast cancer in postmenopausal women, first or second line

Breast cancer is the most common cancer in the UK. Most women who get breast cancer are over 50 years of age. However, younger women, and in rare cases, men, may also get it. Survival beyond five years from diagnosis is relatively high but it depends on cancer stage at diagnosis, with less chance of […]

Pembrolizumab in addition to Chemotherapy for Locally Advanced, Non-Metastatic Triple Negative Breast Cancer – neoadjuvant, first line

Breast cancer is cancer that develops from breast tissue. Triple negative breast cancer (TNBC) is an uncommon type of breast cancer, whose cells don’t have receptors for the hormones oestrogen and progesterone and HER2 protein. Many breast cancers have receptors for one or more of these substances. But TNBC do not have any of them. […]

Bosutinib (Bosulif) for Philadelphia positive chronic myeloid leukaemia – first line

Bosutinib is a treatment that is already available for those patients who have not responded to previous treatments for CML. It is taken as a once-daily tablet and works by blocking certain signals in abnormal white blood cells and inhibiting cancer cell growth. Ongoing development of bosutinib is testing whether or not this treatment can […]

BMS-986165 for moderate to severe plaque psoriasis

BMS-986165 is in clinical development for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Psoriasis is an inflammatory disease whereby the body’s immune system becomes over-active resulting in the life cycle of skin cells to drastically speed up. This causes a build-up of red, scaly, flaky and itchy patches of […]

Bis-choline tetrathiomolybdate for Wilson's disease

Bis-choline tetrathiomolybdate is in clinical development for the treatment of Wilson’s disease (WD). WD is a genetic disorder that prevents the body from removing extra copper, causing copper to build up in the liver, brain, eyes, and other organs. The copper overload in WD is either treated with chelators or zinc. Despite current therapies, there […]

Bimekizumab for non-radiographic axial spondyloarthritis

Bimekizumab is in clinical development for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA). This condition affects patients predominantly in the spine and other areas of the body and is caused by inflammation. This inflammation can lead to back pain, fatigue and in serious cases, to severe disability as the bones of the spine […]

Bimekizumab for active psoriatic arthritis

Bimekizumab is in clinical development for the treatment of adults with psoriatic arthritis which is a type of chronic inflammatory arthritis affecting the joints and connective tissue and is associated with psoriasis of the skin or nails. Although the exact cause of the disease remains unknown, it is thought to occur as a result of […]